why choose us

First received: April 24, 2025

Clinical Trial: Phase I Study With V-212 Vaccinations in Healthy Adult Volunteers

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Healthy
Immunisation Against Streptococcus Pneumoniae

Study Type: INTERVENTIONAL


Official Title: A Prospective, Randomised, Placebo-controlled, Double-blind First in Human Trial Evaluating the Safety and Immunogenicity of V-212 Administered on Three Occasions in Healthy Adult Volunteers.

Brief Summary: Virometix AG, is conducting research into a vaccine (V-212) to prevent pneumococcal disease, which is any type of illness caused by infection with a bacterium called Streptococcus pneumoniae (S. pneumoniae).This trial is being conducted to obtain insight into the body's immune response and possible adverse effects of the trial vaccine in healthy adult volunteers. Three different doses will be evaluated to identify an optimal dose for future trials.The trial is a prospective (collects data into the future),…

Read more